Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]

Detalles Bibliográficos
Autores principales: Dwi Rizkita, Leonny, Astuti, Indwiani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2022
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770015/
https://www.ncbi.nlm.nih.gov/pubmed/36573113
http://dx.doi.org/10.1016/j.jpha.2022.11.001
_version_ 1784854499619241984
author Dwi Rizkita, Leonny
Astuti, Indwiani
author_facet Dwi Rizkita, Leonny
Astuti, Indwiani
author_sort Dwi Rizkita, Leonny
collection PubMed
description
format Online
Article
Text
id pubmed-9770015
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Xi'an Jiaotong University
record_format MEDLINE/PubMed
spelling pubmed-97700152022-12-22 Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271] Dwi Rizkita, Leonny Astuti, Indwiani J Pharm Anal Corrigendum Xi'an Jiaotong University 2022-12 2022-12-21 /pmc/articles/PMC9770015/ /pubmed/36573113 http://dx.doi.org/10.1016/j.jpha.2022.11.001 Text en © 2022 Xi’an Jiaotong University. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Corrigendum
Dwi Rizkita, Leonny
Astuti, Indwiani
Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]
title Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]
title_full Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]
title_fullStr Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]
title_full_unstemmed Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]
title_short Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]
title_sort corrigendum to “the potential of mirna-based therapeutics in severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection: a review” [j. pharma. anal. 11 (2021) 265–271]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770015/
https://www.ncbi.nlm.nih.gov/pubmed/36573113
http://dx.doi.org/10.1016/j.jpha.2022.11.001
work_keys_str_mv AT dwirizkitaleonny corrigendumtothepotentialofmirnabasedtherapeuticsinsevereacuterespiratorysyndromecoronavirus2sarscov2infectionareviewjpharmaanal112021265271
AT astutiindwiani corrigendumtothepotentialofmirnabasedtherapeuticsinsevereacuterespiratorysyndromecoronavirus2sarscov2infectionareviewjpharmaanal112021265271

Ejemplares similares